Monte Rosa Therapeutics (GLUE) Projected to Release Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.3657) per share and revenue of $12.9140 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Trading Up 4.0%

Monte Rosa Therapeutics stock traded up $0.61 during mid-day trading on Tuesday, hitting $15.99. The company’s stock had a trading volume of 385,449 shares, compared to its average volume of 1,391,665. Monte Rosa Therapeutics has a 1 year low of $4.12 and a 1 year high of $25.77. The firm has a market capitalization of $1.35 billion, a PE ratio of -10.81 and a beta of 1.59. The stock’s fifty day moving average is $20.81 and its two-hundred day moving average is $19.54.

Analysts Set New Price Targets

A number of analysts recently issued reports on GLUE shares. JPMorgan Chase & Co. raised their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wedbush reduced their price target on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a research note on Monday. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Finally, Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.67.

Insider Buying and Selling

In other news, insider Sharon Townson sold 6,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $23.31, for a total transaction of $139,860.00. Following the sale, the insider owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anthony M. Manning sold 10,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the sale, the director owned 10,000 shares in the company, valued at approximately $231,100. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 81,778 shares of company stock worth $1,768,581 over the last ninety days. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC acquired a new stake in Monte Rosa Therapeutics in the first quarter valued at approximately $1,065,000. Goldman Sachs Group Inc. grew its holdings in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock worth $1,652,000 after acquiring an additional 196,238 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 1st quarter valued at approximately $76,000. Geode Capital Management LLC raised its holdings in shares of Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after purchasing an additional 120,098 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Monte Rosa Therapeutics by 301.4% in the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock valued at $1,818,000 after purchasing an additional 302,639 shares in the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.